

Moon Seok Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7032769/publications.pdf>

Version: 2024-02-01

93
papers

2,106
citations

257101

24
h-index

288905

40
g-index

96
all docs

96
docs citations

96
times ranked

3071
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	6.1	149
2	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	3.6	144
3	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015, 62, 694-701.	3.6	106
4	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. <i>American Journal of Gastroenterology</i> , 2012, 107, 561-567.	0.2	104
5	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	3.6	68
6	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 2023-2032.	3.6	66
7	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. <i>Liver International</i> , 2018, 38, 1442-1448.	1.9	65
8	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	1.1	64
9	Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. <i>Gut and Liver</i> , 2014, 8, 58-63.	1.4	64
10	The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?. <i>Liver International</i> , 2016, 36, 1490-1497.	1.9	51
11	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	1.8	50
12	Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3235-3242.	1.1	44
13	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. <i>PLoS ONE</i> , 2015, 10, e0124434.	1.1	43
14	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	4.5	42
15	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 516-528.	4.5	42
16	Long-term survival after surgical resection for huge hepatocellular carcinoma: Comparison with transarterial chemoembolization after propensity score matching. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1043-1048.	1.4	38
17	Clinicopathologic Characteristics and Long-Term Prognosis of Scirrhus Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1698-1707.	1.1	37
18	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1593-1603.	2.0	32

#	ARTICLE	IF	CITATIONS
19	The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1465-1472.	1.0	31
20	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. <i>Liver Cancer</i> , 2021, 10, 52-62.	4.2	30
21	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2014, 234, 270-275.	0.4	29
22	A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 813-817.	0.4	28
23	Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2020, 146, 187-193.	0.3	28
24	Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2014, 32, 14.	0.7	28
25	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 47794-47807.	0.8	24
26	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1100-1106.	1.4	23
27	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	1.1	23
28	A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. <i>Hepatology</i> , 2019, 70, 621-629.	3.6	23
29	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 477-486.	4.5	23
30	Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study. <i>Korean Journal of Radiology</i> , 2019, 20, 1616.	1.5	22
31	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	1.4	22
32	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	1.9	21
33	Current status and strategies for viral hepatitis control in Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 189-195.	4.5	21
34	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. <i>Annals of Surgical Treatment and Research</i> , 2020, 99, 238.	0.4	20
35	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 32.	0.7	19
36	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 636-646.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2028-2035.	1.4	17
38	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2016, 10, 939-947.	1.4	15
39	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 3785.	1.4	15
40	Life-sustaining treatment and palliative care in patients with liver cirrhosis - legal, ethical, and practical issues. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 115-122.	4.5	15
41	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	1.9	15
42	Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines. <i>Gut and Liver</i> , 2010, 4, 15-24.	1.4	15
43	Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors. <i>Gut and Liver</i> , 2014, 8, 543-551.	1.4	15
44	Correlation between sonographic findings and infection intensity in clonorchiasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 1139-44.	0.6	15
45	Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1300.	1.7	14
46	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. <i>Digestive and Liver Disease</i> , 2021, 53, 1004-1010.	0.4	14
47	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2016, 10, 295.	1.4	14
48	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. <i>Gut and Liver</i> , 2016, 10, 796-802.	1.4	14
49	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3354-3362.	1.1	13
50	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	1.0	13
51	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	4.5	13
52	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7647.	1.6	13
53	The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 283.	4.5	12
54	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. <i>Journal of Korean Medical Science</i> , 2015, 30, 1618.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. PLoS ONE, 2019, 14, e0213547.	1.1	12
56	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial. Oncotarget, 2017, 8, 52651-52664.	0.8	12
57	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatology International, 2013, 7, 1010-1018.	1.9	11
58	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. Korean Journal of Internal Medicine, 2020, 35, 65-78.	0.7	11
59	Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Digestive Diseases and Sciences, 2022, 67, 4565-4573.	1.1	11
60	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study. Hepatology, 2021, 74, 2988-2997.	3.6	10
61	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clinical and Translational Gastroenterology, 2021, 12, e00290.	1.3	9
62	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. Journal of Viral Hepatitis, 2020, 27, 739-746.	1.0	8
63	Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?. Cancers, 2020, 12, 2395.	1.7	7
64	Cause of Mortality for Hepatocellular Carcinoma Patients who were Diagnosed within the Milan Criteria. Journal of Liver Cancer, 2016, 16, 101-107.	0.3	7
65	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clinical and Molecular Hepatology, 2015, 21, 232.	4.5	7
66	The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study. Gut and Liver, 2012, 6, 241-248.	1.4	7
67	Laparoscopic Hepatic Resection Versus Laparoscopic Radiofrequency Ablation for Subcapsular Hepatocellular Carcinomas Smaller Than 3 cm: Analysis of Treatment Outcomes Using Propensity Score Matching. Korean Journal of Radiology, 2022, 23, 615.	1.5	7
68	Enhanced Resolution of Eosinophilic Liver Abscess Associated with Toxocariasis by Albendazole Treatment. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 222.	0.2	6
69	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. International Journal of Hyperthermia, 2016, 32, 331-338.	1.1	6
70	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 12.	0.9	6
71	The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. Cancers, 2022, 14, 2081.	1.7	6
72	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. Scandinavian Journal of Gastroenterology, 2018, 53, 727-733.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2816-2825.	1.1	5
74	Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients—Functional cure unlikely. <i>Journal of Viral Hepatitis</i> , 2020, 27, 951-954.	1.0	5
75	Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 2614.	1.6	5
76	Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3517-3534.	1.2	5
77	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. <i>PLoS ONE</i> , 2015, 10, e0144777.	1.1	5
78	Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 69-75.	0.8	5
79	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 1082-1087.	0.7	5
80	A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. <i>Hepatology International</i> , 2013, 7, 106-110.	1.9	4
81	Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. <i>Journal of Korean Medical Science</i> , 2014, 29, 1113.	1.1	4
82	Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 393.	4.5	4
83	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	0.6	3
84	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.4	2
85	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. <i>Korean Journal of Transplantation</i> , 2021, 35, 24-32.	0.0	2
86	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3794-3800.	1.1	1
87	Diffuse Pulmonary Meningotheliomatosis - A Case Report -. <i>Korean Journal of Pathology</i> , 2011, 45, S32.	1.2	1
88	Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment. <i>PLoS ONE</i> , 2022, 17, e0262750.	1.1	1
89	Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e168.	1.1	0
90	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2020, 52, 881-888.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	0.6	0
92	TT virus infection in patients on maintenance hemodialysis in Korea. <i>Hepato-Gastroenterology</i> , 2003, 50, 170-3.	0.5	0
93	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-8.	0.6	0